Johnson & Johnson to Establish Advanced Cell Therapy Facility in Pennsylvania
The global leader in biopharmaceuticals is set to enhance its footprint in Pennsylvania with a new state-of-the-art cell therapy manufacturing site.
This significant investment by Johnson & Johnson underscores Pennsylvania’s robust life sciences sector, a vital component in the Commonwealth’s Economic Development Strategy.
Harrisburg, PA – The Department of Community and Economic Development Secretary, Rick Siger, announced today that Johnson & Johnson, a global healthcare titan, will further invest in Pennsylvania by constructing a next-generation cell therapy manufacturing facility. This initiative not only strengthens Johnson & Johnson’s existing operations in the state but is also expected to generate numerous advanced manufacturing jobs.
“The Shapiro Administration is competing hard and promoting Pennsylvania as the best state in the country for businesses to thrive, and we’re thrilled that Johnson & Johnson is continuing to invest in our Commonwealth,” stated Secretary Siger. “Pennsylvania is a national leader in the biotech and life sciences industry, offering companies a strategic location, world-class research infrastructure, and a highly skilled workforce. The Shapiro Administration looks forward to our continuing work with Johnson & Johnson as they grow and succeed here in the Commonwealth.”
Focusing on innovative medicine and MedTech solutions, Johnson & Johnson aims to significantly impact health on a global scale. The company, which currently employs over 138,000 individuals globally, maintains a strong presence in Pennsylvania with several research, development, and manufacturing facilities.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, expressed, “Our investment in a next generation cell therapy manufacturing facility in Pennsylvania builds on Johnson & Johnson’s 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges. The new facility will increase our already significant footprint in the Commonwealth, adding U.S.-based jobs to manufacture cutting edge medicines for patients.”
This move is part of a broader expansion of Pennsylvania’s biotech ecosystem. Companies such as Eurofins, Apozeal Pharmaceuticals, B. Braun, and GSK have also announced significant expansions in the state, contributing to job creation and research and development investments.
The life sciences sector in Pennsylvania employs more than 100,000 people across nearly 3,100 companies and research institutions. The state ranks fourth nationally for new life sciences patents over the past five years, with over 10,700 patents filed.
Since the Shapiro Administration began, over $35.9 billion in private sector investments have been secured, resulting in the creation of more than 18,800 jobs.
Pennsylvania’s Business Climate and Economy Earns Accolades
- Pennsylvania is the sole Northeastern state with a growing economy, as highlighted in a report from Axios based on Moody’s Analytics by Chief Economist Mark Zandi.
- Area Development ranked Pennsylvania among the top 20 “Best States for Business,” and within the top 10 for “Site Readiness Programs.”
- According to Site Selection Magazine, Pennsylvania ranks among the top business climates in the nation, positioned 11th in the 2025 Business Climate Rankings, an improvement of seven places from last year.
- Data from the U.S. Bureau of Labor Statistics shows Pennsylvania ranks among the top states for five-year new business survival, highlighting the strength and resilience of the state’s economy.
Read More Here
